![]() To our knowledge, this is the first report of PRO data for a PD-1/PD-L1 inhibitor in a tumour-agnostic population. For patients with PD, scores were unchanged for symptoms of nausea and vomiting (4.26 ), pain (3.15 ), dyspnea (5.56 ), insomnia (−1.11 ), appetite loss (3.33 ), constipation (1.48 ), diarrhoea (−1.85 ), and financial difficulties (−0.37 ), but worsened for fatigue (5.19 ). For patients with SD, symptom scores improved for dyspnea (−8.18 ), and insomnia (−10.69 ) scores were unchanged for nausea and vomiting (0.63 ), fatigue (−2.31 ), pain (−5.35 ), appetite loss (−1.89 ), constipation (−1.26 ), diarrhoea (−4.40 ), and financial difficulties (0.00 ). For patients with CR/PR, scores improved for fatigue (−7.36 ), nausea and vomiting (−3.49 ), pain (−11.82 ), appetite loss (−13.95 ), and financial difficulties (−12.79 ) scores were unchanged for dyspnea (−2.33 ), insomnia (−3.88 ), constipation (−4.65 ), and diarrhoea (2.71 ). Improvements from baseline to week 9 were observed for the overall cohort for the QLQ-C30 symptom scales of pain (mean, −4.69 ), insomnia (−4.76 ), and appetite loss (−4.47 Fig. 2B). ![]() For patients with PD, no change was observed in role (−2.59 ) or social functioning (−5.00 ) scores, but scores worsened for physical (−5.41 ), emotional (−4.17 ), and cognitive functioning (−6.48 ). Patients with SD had improvements in role functioning (7.86 ), with no change in physical (0.63 ), emotional (2.99 ), cognitive (−0.31 ) or social functioning (3.77 ) scores. Patients with CR/PR showed improvements from baseline to week 9 in role (9.88 ), physical (5.58 ), emotional (5.62 ), and social functioning (8.33 ) but had no change in cognitive functioning (1.74 ). Among all patients, mean (95% CI) improvements were observed from baseline to week 9 for the QLQ-C30 role functioning scale (4.26 ), whereas scores were stable for social (1.88 ), emotional (1.19 ), physical (−0.06 ), and cognitive functioning (−2.09 Fig. 2A).
0 Comments
Leave a Reply. |